{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Taiwan Medical Devices news", "home_page_url": "https://sharemaestro.com/newsreel/tw/healthcare/medical-devices/", "feed_url": "https://sharemaestro.com/newsreel/tw/healthcare/medical-devices/feed.json", "description": "Latest Medical Devices company headlines from Taiwan, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:e475f04ef2b8dc56d9db3d64d18ec8351a87cf7237042b8597341ec5e8d743ce", "url": "https://finance.yahoo.com/healthcare/articles/avita-medical-targets-q4-2025-210153230.html", "external_url": "https://finance.yahoo.com/healthcare/articles/avita-medical-targets-q4-2025-210153230.html", "title": "Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds", "content_text": "Key Points Interested in Avita Medical Inc.? Here are five stocks we like better. Avita Medical raised its 2025 revenue guidance to $86 million\u2013$89 million, citing sequential growth from $17.6 million to $21.7 million over recent quarters. The company is targeting cash flow breakeven in Q4 2025, supported by declining cash use, stable operating expenses and margins, and $11 million in cash available at the end of Q2. Avita sees significant expansion potential for its RECELL, Cohealyx and PermeaDerm portfolio, with only about 15% penetration in its core U.S. market; reimbursement uncertainty ha", "date_published": "2026-08-16T21:01:53+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "4735"], "_sharemaestro": {"country": "Taiwan", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "4735", "name": "AViTA Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/a77d09ac-1c3c-4905-b7ca-8d320df67dda/"}]}}, {"id": "source:4fa6f249966c2ddb6f2614e91fab723be5d7fbccdb136a72a548e9805fdcb1c2", "url": "https://finance.yahoo.com/healthcare/articles/avita-medical-q2-earnings-call-100347328.html", "external_url": "https://finance.yahoo.com/healthcare/articles/avita-medical-q2-earnings-call-100347328.html", "title": "Avita Medical Q2 Earnings Call Highlights", "content_text": "Key Points Interested in Avita Medical Inc.? Here are five stocks we like better. Second-quarter revenue rose 18% year over year to $21.7 million, driven by RECELL growth and increasing adoption of Cohealyx and PermeaDerm. U.S. RECELL revenue reached $18.5 million, while international revenue increased 26% sequentially. Avita raised its 2026 revenue outlook to $86 million\u2013$89 million, representing 20%\u201324% growth, and expects to reach cash-flow breakeven in the fourth quarter. Operating losses and quarterly cash use both improved from the prior year. RECELL utilization is expanding into smaller", "date_published": "2026-08-07T10:03:47+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "4735"], "_sharemaestro": {"country": "Taiwan", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "4735", "name": "AViTA Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/a77d09ac-1c3c-4905-b7ca-8d320df67dda/"}]}}]}